FDA Panel Backs Use Of AstraZeneca Anticlotting Drug Brilinta
28th Jul 2010 21:51
By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--A Food and Drug Administration panel Wednesday backed the use of ticagrelor, a proposed anticlotting drug developed by AstraZeneca PLC (AZN, AZN.LN), despite concerns the product might not work in U.S. patients. T
Read moreThursday preview: Shell, Astra, BSkyB ...
28th Jul 2010 16:54
Anglo-Dutch titan Royal Dutch Shell is the last of the major integrated oil companies to report in the current results season. Until the recent Gulf of Mexico oil spill debacle it had been languishing somewhat in the shadow of long time rival BP but the travails of its beleaguered rival has taken s
Read moreOn Dow Jones Investment Banker Today: Genzyme, Kirin, Booz Allen
27th Jul 2010 20:08
LONDON (Dow Jones Investment Banker)--The following columns have been published exclusively on Dow Jones Investment Banker in recent days. Many Dow Jones Investment Banker columns contain spreadsheets, video, PDFs and other supporting material. To arrange access to the best of Dow Jones news and opi
Read moreTIP SHEET: Live Oak Health Fund Finds Value In Neglected Areas
27th Jul 2010 12:35
(This article was originally published Monday.) By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Mark Oelschlager treads a different path in running the Live Oak Health Sciences Fund (LOGSX). Unlike some health-care fund managers, he didn't come from a career in the pharm
Read moreUK MARKET TALK ROUNDUP: SHARES GAINING
27th Jul 2010 11:34
Stocks on the rise in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 1034 GMT [Dow Jones] Panmure Gordon & Co analyst Savvas Neophytou says AstraZeneca PLC's (AZN) shares to rise Tuesday on U
Read moreMARKET TALK: AstraZeneca Boost Seen On Brilinta Hopes
27th Jul 2010 11:34
1034 GMT [Dow Jones] Panmure Gordon & Co analyst Savvas Neophytou says AstraZeneca PLC's (AZN) shares to rise Tuesday on U.S. Food and Drug Administration documents, released ahead of a Wednesday advisory panel, which raises hopes for its experimental blood thinner Brilinta. "Our reading of the key
Read moreFDA Questions Effectivness Of AstraZeneca Anticlotting Drug
26th Jul 2010 20:55
By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--The Food and Drug Administration questioned the effectiveness of ticagrelor, a proposed anticlotting drug developed by AstraZeneca PLC (AZN, AZN.LN). The company is seeking FDA approval of the product to prevent hea
Read moreTIP SHEET: Live Oak Health Fund Finds Value In Neglected Areas
26th Jul 2010 20:00
By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Mark Oelschlager treads a different path in running the Live Oak Health Sciences Fund (LOGSX). Unlike some health-care fund managers, he didn't come from a career in the pharmaceutical industry or a medical background, and he a
Read moreMARKET TALK: FDA Servers Down, Review Of Brilinta Delayed
26th Jul 2010 17:19
12:19 (Dow Jones) The posting of FDA's review of AstraZeneca's (AZN) proposed anticlotting drug Brilinta has been delayed because some of FDA's servers are down. The agency lost electricity yesterday after severe storms cut power to much of Montgomery County Maryland, where FDA is located. AZN off a
Read moreEARNINGS PREVIEW: AstraZeneca 2Q Seen Strong, 2H To Get Tough
26th Jul 2010 16:27
AstraZeneca PLC (AZN): 2Q Due: July 29 at 0600 GMT DJ Survey of 10 Analysts Average Net Profit: $1.94Bln, up 13% ($1.71Bln in 2Q 2009) Average Sales 2Q 2010: $8.03Bln, up 1% ($7.96Bln in 2Q 2009) Note: Evolution Securities says AstraZeneca looks set to release strong 2Q results helped by limite
Read moreEARNINGS FORECAST TABLE: AstraZeneca 2Q 2010
26th Jul 2010 15:22
FRANKFURT (Dow Jones)--The following is a summary of analysts' forecasts for AstraZeneca plc's (AZN) second-quarter results, based on a poll of 10 analysts by Dow Jones Newswires (in million USD, EPS, dividend in USD, target price in pence, according to IFRS). Earnings figures are scheduled to be re
Read moreTechMARK movers: Microsoft deal boosts ARM
23rd Jul 2010 15:09
Shares in chip designer ARM have jumped on the back of a new licensing deal with Microsoft. The architecture licence will extend the collaborative relationship that has been ongoing since 1997. AstraZeneca is sliding on worries over whether or not its new heart drug Brilinta will be approved by
Read moreWockhardt Gets US OK To Sell Generic Heart Drug
23rd Jul 2010 11:11
BANGALORE (Dow Jones)--Wockhardt Ltd. (532300.BY) Friday said it has received final approval from the U.S. Food & Drug Administration to sell a generic version of AstraZeneca PLC's (AZN) Toprol extended-release tablets for the treatment of heart problems. Wockhardt will immediately launch the pr
Read morePRESS RELEASE: AstraZeneca and Grace Hill Neighborhood Health Centers, Inc. Provide Medicines to Missouri's Uninsured
21st Jul 2010 14:00
WILMINGTON, Del., July 21 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that it is providing medicines at no cost to qualifying patients at Grace Hill Neighborhood Health Centers, Inc. in St. Louis. (Logo: http://photos.prnewswire.com/prnh/20091027/PH99766LOGO ) (Logo: ht
Read moreUPDATE:FDA Questions Benefit, Risks Of Avastin In Breast Cancer
16th Jul 2010 16:03
(Updates with additional information from FDA starting in second paragraph and adds background.) By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--The Food and Drug Administration questioned the benefit of using Roche Holding AG's (RHHBY, ROG.VX) top-selling can
Read more